Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy Transaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment options in rare disease DUBLIN, Sept. 15, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. ("Actio") for $820 million upfront.